You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In PNAS this week: study of central nervous system inflammation roots, circulating immune cells in cancer reflect patient response to treatment, and more.
Because of coronavirus-related shutdowns of customer labs, the San Diego-based firm saw decreased revenues in all geographic regions, especially outside the US.
In PNAS this week: gene-edited mouse model of small cell lung cancer, cystic fibrosis carrier-related conditions, and more.
In Genome Research this week: links between biological aging and mutations affecting epigenetic regulators; long-read sequencing-based strategy to map chromatin accessibility; and more.
Speakers during a session on research rigor and reproducibility said that cores could help push researchers to adopt practices that improve reproducibility.
Six microRNAs appeared to be present at enhanced levels in cerebrospinal fluid from symptom-free individuals with characteristic Huntington disease gene expansions.
The National Network of Libraries of Medicine will support community engagement efforts by public libraries across the US and help improve participant access.
The licenses cover IP related to a new CRISPR technology known as Cpf1, advanced forms of Cas9, and additional Cas9-based genome editing technologies.
Artificial tRNAs may allow cells to read through premature stop codons and treat genetic diseases, New Scientist reports.
Common honeybee viruses were present at low levels in most wild-caught bees from Iowa, but did not produce obvious mortality changes in the non-honeybee species.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.